A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with carboplatin and etoposide in extensive stage small cell lung cancer

Cancer Investigation

Volumn 23, Issue 6, 2005, Pages 511-519

  Gillenwater, Heidi H ^a,c   McCune, Jeannine S ^a   Lindley, Celeste ^a   Faucette, Stephanie ^a   Shord, Stacy ^a   Donahue, Angela ^a   Socinski, Mark A ^a   Stewart, Clinton F ^b   Zamboni, William C ^b   Kirstein, Mark N ^b   Moore, Dominic ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Carboplatin; Etoposide; Extensive stage; MTSE; Small cell lung cancer; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CREATININE; ETOPOSIDE; HEMOGLOBIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TECHNETIUM; TOPOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DEATH; DRUG CLEARANCE; DRUG EFFICACY; ERYTHROCYTE CONCENTRATE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LUNG CANCER; LUNG SMALL CELL CANCER; MALAISE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; STOMATITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, SMALL CELL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL; TOPOTECAN; TREATMENT OUTCOME;

EID: 26844574581     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500201400     Document Type: Article

References (35)

1. Jemal, A.; Tiwari, R.C.; Murray, T.; Ghafoor, A.; Samuels, A.; et al. Cancer Statistics. Cancer J. Clin. 2004, 54 (1), 8-29.
2. Skarlos, D.V.; Samantas, E.; Kosmidis, P.; Fountzilas, G.; Angelidou, M.; et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Cooperative Oncology Group study. Ann. Oncol. 1994, 5 (7), 601-607.
3. Aisner, J. Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. J. Clin. Oncol. 1996, 14 (2), 658-665.
4. Ardizzoni, A.; Hansen, H.; Dombernowsky, P.; Gamucci, T.; Kaplan, S.; et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol. 1997, 15 (5), 2090-2096.
5. Schiller, J.H.; Kim, K.; Hutson, P.; DeVore, R.; Glick, J.; Stewart, J.; Johnson, D. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. 1996, 14 (8), 2345-2352.
6. von Pawel, J.; Schiller, J.H.; Shepherd, F.A.; Fields, S.Z.; Kleisbauer, J.P.; et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. 1999, 17 (2), 658-667.
7. Cheng, M.F.; Chatterjee, S.; Berger, N.A. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol. Res. 1994, 6 (6), 269-279.
8. Bonner, J.A.; Kozelsky, T.F. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother. Pharmacol. 1996, 39 (1-2), 109-112.
9. Gurney, H. Dose calculation of Anti-Cancer Drugs: a review of the current practice and introduction of an alternative. J. Clin. Oncol. 1996, 14 (9), 2590-2611.
10. Wall, J.G.; Burris, H.A.D.; Von Hoff, D.D.; Rodriguez, G.; Kneuper-Hall, R.; et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-Cancer Drugs 1992, 3 (4), 337-345.
11. Saltz, L.; Sirott, M.; Young, C.; Tong, W.; Niedzwiecki, D.; et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J. Natl. Cancer Inst. 1993, 85 (18), 1499-1507.
12. van Warmerdam, L.J.; Verweij, J.; Schellens, J.H.; Rosing, H.; Davies, B.E.; et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol. 1995, 35 (3), 237-245.
13. Abbruzzese, J.L.; Madden, T.; Sugarman, S.M.; Ellis, A.L.; Loughlin, S.; et al. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin. Cancer Res. 1996, 2 (9), 1489-1497.
14. Herben, V.M.; ten Bokkel Huinink, W.W.; Beijnen, J.H. Clinical pharmacokinetics of topotecan. Clin. Pharmacokinet. 1996, 31 (2), 85-102.
15. Furman, W.L.; Baker, S.D.; Pratt, C.B.; Rivera, G.K.; Evans, W.E.; Stewart, C.F. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J. Clin. Oncol. 1996, 14 (5), 1504-1511.
16. Grochow, L.B.; Rowinsky, E.K.; Johnson, R.; Ludeman, S.; Kaufmann, S.H.; et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos. 1992, 20 (5), 706-713.
17. Newell, D.R. Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy? Ann. Oncol. 1994, 5 (Suppl. 4), 9-14 discussion 15.
18. Calvert, A.H.; Newell, D.R.; Gumbrell, L.A.; O'Reilly, S.; Burnell, M.; et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function [see comments]. J. Clin. Oncol. 1989, 7 (11), 1748-1756.
19. Evans, W.E. Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Blut 1988, 56 (6), 241-248.
20. Sugita, O.; Uchiyama, K.; Yamada, T.; Sato, T.; Okada, M.; Takeuchi, K. Reference values of serum and urine creatinine, and of creatinine clearance by a new enzymatic method. Ann. Clin. Biochem. 1992, 29 (Pt. 5), 523-528.
21. Joel, S.P.; Shah, R.; Clark, P.I.; Slevin, M.L. Predicting etoposide toxicity: relationship to organ function and protein binding. J. Clin. Oncol. 1996, 14 (1), 257-267.
22. Stewart, C.F. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother. Pharmacol. 1994, 34 (Suppl.), S76-S83.
23. Hande, K.R.; Krozely, M.G.; Greco, F.A.; Hainsworth, J.D.; Johnson, D.H. Bioavailability of low-dose oral etoposide. J. Clin. Oncol. 1993, 11 (2), 374-377.
24. Gentili, D.; Zucchetti, M.; Torn, V.; Sessa, C.; de Jong, J.; Cavalli, F.; D'Incalci, M. A limited sampling model for the pharmacokinetics of etoposide given orally. Cancer Chemother. Pharmacol. 1993, 32 (6), 482-486.
25. Stewart, C.F.; Baker, S.D.; Heideman, R.L.; Jones, D.; Crom, W.R.; Pratt, C.B. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J. Clin. Oncol. 1994, 12 (9), 1946-1954.
26. Zamboni, W.C.; Gajjar, A.J.; Heideman, R.L.; Beijnen, J.H.; Rosing, H.; Houghton, P.J.; Stewart, C.F. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin. Cancer Res. 1998, 4 (3), 783-789.
27. Ormrod, D.; Spencer, C.M. Topotecan: a review of its efficacy in small cell lung cancer. Drugs 1999, 58 (3), 533-551.
28. Rowinsky, E.K.; Kaufmann, S.H.; Baker, S.D.; Grochow, L.B.; Chen, T.L.; et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence [see comments]. J. Clin. Oncol. 1996, 14 (12), 3074-3084.
29. Baker, S.D.; Verweij, V.; Rowinsky, E.K.; Donehower, R.C.; et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J. Natl. Cancer Inst. 2002, 94 (24), 1833-1838.
30. Rowinsky, E.K.; Grochow, L.B.; Hendricks, C.B.; Ettinger, D.S.; Forastiere, A.A.; et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol. 1992, 10 (4), 647-656.
31. Gallo, J.M.; Laub, P.B.; Rowinsky, E.K.; Grochow, L.B.; Baker, S.D. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J. Clin. Oncol. 2000, 18 (12), 2459-2467.
32. Mould, D.R.; Holford, N.H.G.; Schellens, J.H.; Beijnen, J.H.; Hutson, P.; et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin. Pharmacol. Ther. 2002, 71 (5), 334-348.
33. Loehrer, P.J., Sr.; Ansari, R.; Gonin, R.; Monaco, F.; Fisher, W.; Sandler, A.; Einhorn, L.H. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J. Clin. Oncol. 1995, 13 (10), 2594-2599.
34. Treat, J. Weekly topotecan in the management of lung cancer. Lung Cancer 2003, 41 (Suppl. 4), S27-S31.
35. Greco, F.A.; Hainsworth, J.D. Emerging role of topotecan in first-line therapy of small-cell lung cancer. Clin. Lung Cancer 2003, 4 (5), 279-287.